APOLLO has a streamlined and standardized process for:
- gathering high-quality biopsies and conducting biospecimen draws before, during and at the end of treatment
- preparing samples for deep genomic/molecular analysis and immune response monitoring
- storing results in the Translational Research Accelerator platform, which is the first and currently only truly integrated clinical and research data platform made for cancer research
APOLLO has been used successfully in leukemia, sarcoma and melanoma pilot projects. In the next two years, it is scheduled to conduct analyses in 2,100 patients enrolled on 28 high-priority clinical trials for lung, breast, colorectal, pancreas, ovarian and HPV-related cancers, as well as multiple myeloma, glioblastoma, lymphoma and sarcoma.
APOLLO has standard-changing potential. The platform will enable deep longitudinal molecular profiling of even the rarest cancers, populating the most comprehensive, patient-centric and clinically driven molecular cancer dataset anywhere.
- Andy Futreal, Ph.D., professor, Genomic Medicine
- Cynthia Powers, director of Ambulatory Work Standardization